Fandom

VroniPlag Wiki

Ww/012

< Ww

31.377Seiten in
diesem Wiki
Seite hinzufügen
Diskussion0 Teilen

Störung durch Adblocker erkannt!


Wikia ist eine gebührenfreie Seite, die sich durch Werbung finanziert. Benutzer, die Adblocker einsetzen, haben eine modifizierte Ansicht der Seite.

Wikia ist nicht verfügbar, wenn du weitere Modifikationen in dem Adblocker-Programm gemacht hast. Wenn du sie entfernst, dann wird die Seite ohne Probleme geladen.

Validation of shRNA clones for gene silencing in 293FT cells

von Dr. Wen Wang

vorherige Seite | zur Übersichtsseite | folgende Seite
Statistik und Sichtungsnachweis dieser Seite findet sich am Artikelende
[1.] Ww/Fragment 012 01 - Diskussion
Zuletzt bearbeitet: 2014-10-29 07:50:54 Hindemith
Fragment, Gesichtet, Hammond 2005, SMWFragment, Schutzlevel sysop, Verschleierung, Ww

Typus
Verschleierung
Bearbeiter
SleepyHollow02
Gesichtet
Yes.png
Untersuchte Arbeit:
Seite: 12, Zeilen: 1-20
Quelle: Hammond 2005
Seite(n): 5825 f., Zeilen: 5825: r.col. last lines; 5826: l.co. 1 ff., 26 ff.
Structurally, this protein family is characterized by two domains, the PAZ domain and the PIWI domain. Structures for both domains have been solved. Additional RISC components with unknown roles in RNAi have also been identified. These include the RNA binding protein VIG, the Drosophila homolog of the Fragile X protein, dFXR, helicase proteins, and Tudor-SN (Ishizuka et al, 2002; Caudy et al, 2003). This last protein has five staphylococcal nuclease (SNase) domains and a Tudor domain. In humans, there are four closely related Argonaute family members, named Ago1-4. All four bind siRNAs and miRNAs at similar levels, and are widely expressed. Only Ago2, however, is present in a cleavage-competent RISC-complex (Meister et al, 2004). Similarly, siRNA-mediated knockdown, or targeted knockout, of Ago2 impaired RNAi of a reporter, while knockdown of Ago1, 3, 4 had no effect. The crystal structure of an Argonaute family member from Pyrococcus furiosus has been revealed (Song et al, 2004). The structure displayed an RNaseH fold for the signature PIWI domain. The crystal structure of a second archaean argonaute, Archaeoglobus fulgidus Piwi (AfPiwi), confirmed the RNaseH fold (Parker et al, 2004). The final demonstration that Slicer activity was contained within Ago2 was the reconstitution of minimal RISC with bacterially expressed, purified Ago2 and a single-stranded siRNA (Rivas et al, 2005). Structurally, this protein family is characterized by two domains, the PAZ domain and the PIWI domain. Structures for both domains have been solved (see below). Additional RISC components with unknown roles in RNAi

[5826:]

have also been identified. These include the RNA binding protein VIG, the Drosophila homolog of the Fragile X protein, dFXR, helicase proteins, and Tudor-SN [46–48]. This last protein has five staphylococcal nuclease (SNase) domains and a Tudor domain. [...]

[...]

[...] In humans, there are four closely related Argonaute family members, named Ago1-4. All four bind siRNAs and microRNAs at similar levels, and are widely expressed. Only Ago2, however, is present in a cleavage- competent RISC [52,53]. Similarly, siRNA-mediated knockdown, or targeted knockout, of Ago2 impairs RNAi of a reporter, while knockdown of Ago1, 3, 4 had no effect. These data can be interpreted in two ways: Ago2 alone is capable of interacting with Slicer, or Ago2 itself is Slicer. The answer was provided by the crystal structure of an Argonaute family member from Pyrococcus furiosus [54]. The structure revealed an RNaseH fold for the signature PIWI domain. The crystal structure of a second archaean Argonaute, Archaeoglobus fulgidus Piwi (AfPiwi), confirmed the RNaseH fold [55]. The final demonstration that Slicer activity was contained within Ago2 was the reconstitution of minimal RISC with bacterially expressed, purified Ago2 and a single-stranded siRNA [45].


[46] Caudy, A.A., Myers, M., Hannon, G.J. and Hammond, S.M. (2002) Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 16, 2491–2496.

[47] Caudy, A.A. et al. (2003) A micrococcal nuclease homologue in RNAi effector complexes. Nature 425, 411–414.

[48] Ishizuka, A., Siomi, M.C. and Siomi, H. (2002) A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 16, 2497–2508.

[52] Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G. and Tuschl, T. (2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185–197.

[53] Liu, J. et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437–1441.

[54] Song, J.J., Smith, S.K., Hannon, G.J. and Joshua-Tor, L. (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305, 1434–1437.

[55] Parker, J.S., Roe, S.M. and Barford, D. (2004) Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J. 23, 4727–4737.

Anmerkungen

Kein Hinweis auf die Quelle.

Sichter
(SleepyHollow02), Hindemith

[2.] Ww/Fragment 012 21 - Diskussion
Zuletzt bearbeitet: 2014-10-29 15:50:34 Hindemith
Fragment, Gesichtet, KomplettPlagiat, SMWFragment, Schutzlevel sysop, Stevenson 2004, Ww

Typus
KomplettPlagiat
Bearbeiter
SleepyHollow02
Gesichtet
Yes.png
Untersuchte Arbeit:
Seite: 12, Zeilen: 21 ff.
Quelle: Stevenson 2004
Seite(n): 1773, Zeilen: r.col: 4ff
1.2.2 Therapeutic applications of RNAi

The therapeutic applications of RNAi are potentially enormous. The genetic etiology of many disorders has now been defined and, in some cases, has been targeted by RNAi in in vitro and in vivo model systems. Because the specificity of RNAi is governed by sequence complementarity between the siRNA and the target RNA, the most obvious application would be to treat diseases in which genetic polymorphisms within the disease-inducing gene in a particular lesion or tumor can be targeted for degradation without affecting RNA from wild-type alleles.

Therapeutic Applications

The therapeutic applications of RNAi are potentially enormous. The genetic etiology of many disorders has now been defined and, in some cases, has been targeted by RNAi in in vitro and in vivo model systems. Because the specificity of RNAi is governed by sequence complementarity between the siRNA and the target RNA, the most obvious application would be to treat diseases in which genetic polymorphisms within the disease-inducing gene in a particular lesion or tumor can be targeted for degradation without affecting RNA from wild-type alleles.

Anmerkungen

Kein Hinweis auf die Quelle.

Sichter
(SleepyHollow02), Hindemith


vorherige Seite | zur Übersichtsseite | folgende Seite
Letzte Bearbeitung dieser Seite: durch Benutzer:Hindemith, Zeitstempel: 20141029154717

Auch bei Fandom

Zufälliges Wiki